Evidence map›Paper›PMID 32442262›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020

Ethical and Practical Issues Associated With the Possibility of Using Controlled Human Infection Trials in Developing a Hepatitis C Virus Vaccine.

Andrea Cox, Mark Sulkowski, Jeremy Sugarman

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Ethics of Controlled Human Infection Studies With Hepatitis C Virus.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  2. Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Trial Design Considerations.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  3. Controlled Human Infection Model - Fast Track to HCV Vaccine?The New England journal of medicine · 2021
    Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Andrea CoxSchool of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Mark SulkowskiSchool of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Jeremy SugarmanSchool of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Johns Hopkins Medicine · USJohns Hopkins University · US

Funding

Management/Hepatitis C/HIV-infected and Uninfected IDU'sR01DA016065 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SULKOWSKI, MARK SEBASTIAN · 2003 to 2018
$8.0M
Patient Oriented Research in Hepatitis C-infected Injection Drug UsersK24DA034621 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SULKOWSKI, MARK SEBASTIAN · 2012 to 2022
$1.2M
NIDA NIH HHS K24 DA034621NIDA NIH HHS R01 DA016065
6 · The paper itself

Abstract

Despite the existence of established treatments for hepatitis C virus (HCV), more effective means of preventing infection, such as a vaccine, are arguably needed to help reduce substantial global morbidity and mortality. Given the expected challenges of developing such a vaccine among those at heightened risk of infection, controlled human infection studies seem to be a promising potential approach to HCV vaccine development, but they raise substantial ethical and practical concerns. In this article, we describe some of the challenges related to the possibility of using controlled human infection studies to accelerate HCV vaccine development. The related ethical and practical concerns require further deliberation before such studies are planned and implemented.

Indexed as

Hepatitis CViral Hepatitis VaccinesHepacivirusHepatitis C AntibodiesHumansHepatitis C AntibodiesViral Hepatitis Vaccineschallenge studiescontrolled human infection studiesethicshepatitis C virusvaccines

Identifiers

PMID32442262
PMCPMC7778335
OpenAlexW3027595517

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.